pergularine A



Compound IDCDAMM02499
Common namepergularine A
IUPAC name(4,4,6a,6b,8a,11,14b-heptamethyl-12-methylidene-1,2,3,4a,5,6,6a,7,8,9,10,11,12a,13,14,14a-hexadecahydropicen-3-yl) 4-methylpent-3-enoate
Molecular formulaC36H58O2

Experimental data

Retention time12.59
Adduct[M+Na]+
Actual mz545.433
Theoretical mz545.433
Error0.52
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.4457

Identifiers and class information

Inchi keySOKIHCAMPJLTAJ-XWFTXFNQSA-N
SmilesO=C(OC1CCC2(C)C(CCC3(C)C2CCC4C5C(=C)C(C)CCC5(C)CCC43C)C1(C)C)CC=C(C)C
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)5
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)3
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)1
Molecular weight (mol_MW)522.853
Computed dipole moment(dipole)3.191
Total solvent accessible surface area (SASA)842.065
Hydrophobic component of SASA (FOSA)785.36
Hydrophilic component of SASA (FISA)31.665
Pie component of the SASA (PISA)25.041
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1711.79
Number of hydrogen bond donors (donorHB)0
Number of hydrogen bond acceptors (accptHB)2
Free energy of solvation of dipole (dip^2/V)0.0059488
Index of cohesive interaction in solids (ACxDN^.5/SA)0
Globularity descriptor (glob)0.821839
Predicted polarizability in cubic angstroms (QPpolrz)60.665
Predicted hexadecane/gas partition coefficient (QPlogPC16)14.277
Predicted octanol/gas partition coefficient (QPlogPoct)21
Predicted water/gas partition coefficient (QPlogPw)3.44
Predicted octanol/water partition coefficient (QPlogPo/w)9.299
Predicted aqueous solubility (QPlogS)-10.639
Conformation-independent predicted aqueous solubility (CIQPlogS)-9.207
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.534
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)4961.6
Predicted brain/blood partition coefficient (QPlogBB)0.07
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)2794.05
Predicted skin permeability, log Kp (QPlogKp)-1.727
PM3 calculated ionization potential (IP(ev))9.74
PM3 calculated electron affinity (EA(eV))-0.693
Number of likely metabolic reactions (#metab)5
Prediction of binding to human serum albumin (QPlogKhsa)2.925
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)100
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)31.601
Number of nitrogen and oxygen atoms (#NandO)2
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P11511CYP19A1Cytochrome P450 19A1T13260SwissTargetPrediction
P18031PTPN1Protein-tyrosine phosphatase 1BT16347SwissTargetPrediction and SEA
P17706PTPN2T-cell protein-tyrosine phosphataseT49156SEA
P28845HSD11B111-beta-hydroxysteroid dehydrogenase 1T65200SwissTargetPrediction
Q8TDU6GPBAR1G-protein coupled bile acid receptor 1T86273SEA
Q9Y233PDE10APhosphodiesterase 10A (by homology)T84133SwissTargetPrediction
P30518AVPR2Vasopressin V2 receptor (by homology)T66237SwissTargetPrediction
P05093CYP17A1Cytochrome P450 17A1T89041SwissTargetPrediction
O43614HCRTR2Orexin receptor 2T69485SwissTargetPrediction
O43613HCRTR1Orexin receptor 1T73482SwissTargetPrediction
P25116F2RProteinase-activated receptor 1T36483SwissTargetPrediction
P01584IL1BInterleukin-1 betaT42000SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T13260DI0062Breast cancer[ICD-11: 2C60-2C6Y]P11511CYP19A1
T13260DI0108Cushing syndrome[ICD-11: 5A70]P11511CYP19A1
T16347DI0009Acute diabete complication[ICD-11: 5A2Y]P18031PTPN1
T16347DI0062Breast cancer[ICD-11: 2C60-2C6Y]P18031PTPN1
T16347DI0308Obesity[ICD-11: 5B80-5B81]P18031PTPN1
T16347DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P18031PTPN1
T49156DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P17706PTPN2
T65200DI0210Influenza[ICD-11: 1E30-1E32]P28845HSD11B1
T65200DI0239Lupus erythematosus[ICD-11: 4A40]P28845HSD11B1
T65200DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P28845HSD11B1
T86273DI0417Type 2 diabetes mellitus[ICD-11: 5A11]Q8TDU6GPBAR1
T84133DI0079Choreiform disorder[ICD-11: 8A01]Q9Y233PDE10A
T84133DI0206Inborn purine/pyrimidine/nucleotide metabolism error[ICD-11: 5C55]Q9Y233PDE10A
T84133DI0218Irritable bowel syndrome[ICD-11: DD91]Q9Y233PDE10A
T84133DI0370Schizophrenia[ICD-11: 6A20]Q9Y233PDE10A
T84133DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q9Y233PDE10A
T66237DI0009Acute diabete complication[ICD-11: 5A2Y]P30518AVPR2
T66237DI0041Autism spectrum disorder[ICD-11: 6A02]P30518AVPR2
T66237DI0131Enuresis[ICD-11: 6C00]P30518AVPR2
T66237DI0194Hypo-osmolality/hyponatraemia[ICD-11: 5C72]P30518AVPR2
T66237DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P30518AVPR2
T66237DI0338Polyuria[ICD-11: MF55]P30518AVPR2
T89041DI0346Prostate cancer[ICD-11: 2C82]P05093CYP17A1
T69485DI0214Insomnia[ICD-11: 7A00-7A0Z]O43614HCRTR2
T73482DI0117Depression[ICD-11: 6A70-6A7Z]O43613HCRTR1
T73482DI0214Insomnia[ICD-11: 7A00-7A0Z]O43613HCRTR1
T73482DI0317Opioid use disorder[ICD-11: 6C43]O43613HCRTR1
T36483DI0287Myocardial infarction[ICD-11: BA41-BA43]P25116F2R
T42000DI0267Mineral excesses[ICD-11: 5B91]P01584IL1B
T42000DI0269Monogenic autoinflammatory syndrome[ICD-11: 4A60]P01584IL1B
T42000DI0320Osteoarthritis[ICD-11: FA00-FA05]P01584IL1B
T42000DI0366Rheumatoid arthritis[ICD-11: FA20]P01584IL1B

Copyright © 2025